-
World’s first iPS cell transplant for Parkinson’s
Kyoto University said Friday it has conducted the world’s first transplant of induced pluripotent stem cells to treat Parkinson’s disease.
Nerve cells created from the artificially derived stem cells, known as iPS cells, were transplanted into the brain of a patient in his 50s in October in a treatment researchers hope to develop into a method that can be covered under Japan’s health insurance system.
“By also cooperating with companies, we want to develop a mass production system that enables us to deliver nerve cells derived from iPS cells to all over the world,” said Jun Takahashi
The study will involve seven patients in their 50s and 60s, who fulfilled the criteria of having received drug treatments without effective results and having suffered from Parkinson’s disease for more than five years.“Having heard the news of the first trial, I feel the research is steadily moving forward step by step. We are all looking forward to hearing a positive outcome,” said Hisao Hiramine, a 70-year-old who suffers from the disease and chairs a Tokyo association of patients and their families.
Asked about his eventual goal, Kyoto University’s Takahashi said, “The best scenario is to see patients improve to the extent they do not have to take any medicine.”
-
8 Replies
-
I think this is wonderful news and it gives those with PD hope for someday curing this disease of so many losses. I hope this will be shared with the US.
-
The Center for iPS Cell Research and Application (CiRA), Kyoto University, has announced the construction of a master cell bank (MCB)1 from the CiRA iPS Cell Stock for Regenerative Medicine2 with Takeda Pharmaceutical Company Limited (Takeda).
The MCB construction is part of the Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), a large scale collaboration between CiRA and Takeda that aims to apply iPS cell technologies for treatment of multiple diseases.
The CiRA iPS Cell Stock for Regenerative Medicine (The iPS Cell Stock Project) is preparing and storing multiple iPS cell lines for clinical application. Each line is made by reprogramming cells from healthy donors who are human leukocyte antigen (HLA) homozygous. The use of HLA homozygous donors expands the number of people who can receive the cells in a therapy without a severe immune reaction.
-
Thank you for continuing to keep us in the loop! I hope some researchers/companies in the USA are looking at this.
-
-
Actually https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_companies_by_revenue
Actually Takeda is pretty big top 20 th ine world. about same size of Bristol-Myers and has quite a big entity in the US as well.
I am sure big Amrican comanies are looking at this.
Example
Ono Japanese small pharmaceutical company started to sell cancer cure revolutionary medicine. invented by Mr. Honjo who got Nobel prize this year. and Bristol Myers got interested in the medicine and invested heavyly now Merck is paying a loyalty fee to Ono.
.
-
If there is a lot of money to be made, big Pharma in the USA will become involved.
-
-
Tha is true. For the patients the more companies the more results I hope.
World’s first commercial iPS cell-making plant opens
The new center will use iPS cells created by Kyoto University’s Center for iPS Cell Research and Application (CiRA) and other institutes not only to proliferate them, but to convert them into retina and other cells. These iPS-derived cells can then be shipped to medical centers for treatment use.According to Sumitomo Dainippon Pharma officials, a large amount of cells enough to treat hundreds of patients can be produced annually in each zone of the facility.
Working with the Riken research institute, CiRA, Keio University and other institutions, Sumitomo Dainippon Pharma is developing iPS cell-based products to treat age-related macular degeneration, retinitis pigmentosa and other eye diseases as well as Parkinson’s disease and spinal cord injuries.
The company intends to make regenerative medicine one of its future core businesses and is looking to boost its sales in the field to 200 billion yen ($1.8 billion) by 2030.
-
This Nature’s Article.
https://www.nature.com/articles/d41586-018-07407-9
Reprogrammed’ stem cells implanted into patient with Parkinson’s disease-
Thank you for sharing all of this information, keihanna. Are you a researcher/physician working on PD research?
-
Log in to reply.